Country-specific information: Rationale

Epidemiological rationale for recommendations

The disease information that follows details the rationale and resources used for the NaTHNaC country-specific recommendations. The update dates below do not reflect when the last epidemiological review was completed but the most recent rationale for each disease.

NaTHNaC monitors and continues to respond to disease outbreaks posting information on the Outbreak Surveillance section of the website and will update country-specific recommendations accordingly.

Country-specific recommendations are based on collaborations with UKHSA.

Biting insects or ticks

Regional information about biting insects and ticks that transmit infections including African tick bite fever, Chikungunya, Crimean Congo haemorrhagic fever, leishmaniasis, Murray Valley encephalitis Rift Valley fever, Ross River virus, scrub typhus, trypanosomiasis and West Nile virus are included on the "other risk " section of the country information pages where appropriate.

A regional disease risk is included on a country information page, when there are reports of that disease in at least one country of that United Nations standard geographical sub-region according to the World Health Organization, national authorities or other verified sources.

Updated: July 2018

  1. World Health Organization. Distribution of Crimean Congo Haemorrhagic Fever 2015
  2. World Health Organization. Chikungunya countries or areas at risk 2015
  3. Epidemiological update: West Nile virus transmission season in Europe, 2017
  4. Centers for Disease Control. West Nile Virus: Statistics and Maps
  5. Government of Canada: Surveillance of West Nile Virus
  6. World Health Organization. West Nile Virus Fact Sheet
  7. Pan American Health Organization. West Nile Virus
  8. Pan American Health Organization. West Nile Virus: Epidemiological Alerts and Updates
  9. New South Wales Government. Department of Primary Industries. West Nile virus in Australia
  10. World Health Organization. Rift Valley fever fact sheet
  11. Bosworth A et al (2016). Serologic evidence of exposure to Rift Valley fever virus detected in Tunisia. New Microbe and New Infect 2016; 9: 1–7. Accessed 23 July 2018.
  12. Fontenille D et al (1998). New Vectors of Rift Valley Fever in West Africa. Emerging infectious diseases. Volume 4, Number 2—June. [Accessed 23 July 2018]
  13. Nakouné E et al (2016). Rift Valley Fever Virus Circulating among Ruminants, Mosquitoes and Humans in the Central African Republic. PLOS Neglected Tropical Diseases Oct 19;10(10)
  14. World Health Organization. Mapping the distribution of human African trypanosomiasis
  15. Franco JR et al 2017. PLOS Neglected Tropical Diseases. Monitoring the elimination of human African trypanosomiasis: Update to 2014. PLOS Neglected Tropical diseases 11(5). [Accessed 23 July 2018]
  16. World Health Organization. Global Health Observatory data: Leishmaniasis
  17. Gondard M et al. Ticks and Tick-Borne Pathogens of the Caribbean: Current understanding and future directions for more comprehensive surveillance. Frontiers in Cellular and Infection Microbiology. 7;490. 1-16.[Accessed 23 July 2018]
  18. Xu G et al. A review of the global epidemiology of scrub typhus. PLoS Negl Trop Dis. November 3, 2017. [Accessed 23 July 2018]
  19. Mackenzie JS et al. The ecology and epidemiology of Ross River and Murray Valley encephalitis viruses in Western Australia: examples of One Health in Action. Trans Roy Soc Trop Med & Hyg 2017. [Accessed 23 July 2018]


Cholera is considered to represent a potential risk to travellers if:

  • a country had reported ≥100 cases to the WHO in at least 3 out of 5 years, 2013 to 2017 inclusive;
  • a country had reported an outbreak of ≥1000 cases to the WHO in at least one year, 2013 to 2017 inclusive.

When there had been sporadic or absent reporting to WHO between 2013 and 2017, a consensus opinion regarding risk was formed based on consideration of available data, including Public Health England data on imported cholera cases to the UK and World Health Organization water progress on household drinking water, sanitation and hygiene 2000-2017 [2].

Updated: October 2019


Most countries worldwide now present a potential risk of exposure to COVID-19 for travellers. Each country, territory or area has been reviewed and categorised according to:

  • the risk that travel presents to individual travellers (based on the impact of the additional burden that COVID-19 cases place on healthcare capacity).

  • the risk that travel presents to UK public health (based on the presence of known variants of concern, known emerging or high-risk variants under investigation, or because of very high or rapidly increasing and unexplained prevalence of COVID-19).

Countries have been categorised as either:

  • a country considered to present a high risk of exposure to COVID-19 and where the additional burden of COVID-19 cases has had a considerable impact on healthcare capacity, which may affect the ability access to healthcare in emergencies. All travellers (even if fully vaccinated against COVID-19) are advised to avoid non-essential travel to these countries.

  • rest of the world countries; all travellers should ensure they have access to up to date information on COVID-19 and be prepared for rapid changes in guidance both before and during travel.

Some country pages may also have additional information regarding outbreaks or clusters of cases which are being carefully monitored by our surveillance teams.

At the current time there are no countries considered to present a high public health risk to the UK where all travellers (even if fully vaccinated against COVID-19) are advised to avoid non-essential travel (previously called ‘red list’ countries), but the situation is being monitored and could change at short notice.

There is no one indicator alone that will provide sufficient evidence on the epidemiology of COVID-19 in a country to inform the potential risks for travellers, and there are no agreed international standards for risk categorisation. Travellers and those advising travellers are therefore encouraged to read our risk assessment guidance when planning international travel.

Changes to categorisation will be made as required, in response to changes in risk.

Updated: March 2022


NaTHNaC dengue recommendations are based on published data focussing on evidence of local mosquito-borne dengue transmission from January 2016 to July 2021 [1-23]. For part-endemic countries, further sub-national details have been provided where confirmed.

Updated: July 2021

  1. Jentes, E.S. et al. (2016) Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J. Travel Med. 23(6).
  2. Al-Azraqi, T.A., El Mekki, A.A., Mahfouz, A.A., 2013. Seroprevalence of dengue virus infection in Aseer and Jizan regions, Southwestern Saudi Arabia. Trans. R. Soc. Trop. Med. Hyg. 107, 368–371.
  3. Cotter, C.J., et al., Outbreak of Dengue Virus Type 2 - American Samoa, November 2016-October 2018. MMWR Morb Mortal Wkly Rep, 2018. 67(47): p. 1319-1322.
  4. Centers for Disease Control and Prevention (CDC). Dengue; Statistics and Maps. 15 November 2020.
  5. Chinikar, S., Ghiasi, S.M., Shah-Hosseini, N., Mostafavi, E., Moradi, M., Khakifirouz, S., Rasi Varai, F.S., Rafigh, M., Jalali, T., Goya, M.M., Shirzadi, M.R., Zainali, M., Fooks, A.R., 2013. Preliminary study of dengue virus infection in Iran. Travel Med. Infect. Dis. 11, 166–169.
  6. Gonidec, E.L., Maquart, M., Duron, S., Savini, H., Cazajous, G., Vidal, P.-O., Chenilleau, M.-C., Roseau, J.-B., Benois, A., Dehan, C., Kugelman, J., Leparc-Goffart, I., Védy, S., 2016. Clinical Survey of Dengue Virus Circulation in the Republic of Djibouti between 2011 and 2014 Identifies Serotype 3 Epidemic and Recommends Clinical Diagnosis Guidelines for Resource Limited Settings. PLoS Negl. Trop. Dis. 10, e0004755.
  7. Humphrey, J.M., Cleton, N.B., Reusken, C.B.E.M., Glesby, M.J., Koopmans, M.P.G., Abu-Raddad, L.J., 2016. Dengue in the Middle East and North Africa: A Systematic Review. PLoS Negl. Trop. Dis. 10, e0005194.
  8. Jentes, E.S., Lash, R.R., Johansson, M.A., Sharp, T.M., Henry, R., Brady, O.J., Sotir, M.J., Hay, S.I., Margolis, H.S., Brunette, G.W., 2016. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J. Travel Med. 23.
  9. Kern-Allely, S., A. Pobutsky, and W.T. Hancock, Notes from the Field: First Evidence of Locally Acquired Dengue Since 1944 - Guam, 2019. MMWR Morb Mortal Wkly Rep, 2020. 69(13): p. 387-388.
  10. Kraemer, M.U.G., Sinka, M.E., Duda, K.A., Mylne, A., Shearer, F.M., Brady, O.J., Messina, J.P., Barker, C.M., Moore, C.G., Carvalho, R.G., Coelho, G.E., Bortel, W.V., Hendrickx, G., Schaffner, F., Wint, G.R.W., Elyazar, I.R.F., Teng, H.-J., Hay, S.I., 2015. The global compendium of Aedes aegypti and Ae. albopictus occurrence. Sci. Data 2.
  11. Neumayr, A., Muñoz, J., Schunk, M., Bottieau, E., Cramer, J., Calleri, G., López-Vélez, R., Angheben, A., Zoller, T., Visser, L., Serre-Delcor, N., Genton, B., Castelli, F., Van Esbroeck, M., Matteelli, A., Rochat, L., Sulleiro, E., Kurth, F., Gobbi, F., Norman, F., Torta, I., Clerinx, J., Poluda, D., Martinez, M., Calvo-Cano, A., Sanchez-Seco, M.P., Wilder-Smith, A., Hatz, C., Franco, L., 2017. Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. Eurosurveillance 22.
  12. PAHO, 2017. PAHO WHO | Dengue | PAHO/WHO Data, Maps and Statistics [WWW Document].
  13. ProMED, 2015. DENGUE FEVER - MAURITANIA (03): (NOUAKCHOT) [WWW Document]. ProMED-Mail Post Middle EastNorth Afr.
  14. ProMED. Dengue/DHF update (17): Asia, Pacific, Europe, Africa 2019 [cited 2020 22/07/2020].
  15. ProMED International Society for Infectious Diseases. Dengue/DHF update (05): Americas. 2020 [cited 2020 22/07/2020].
  16. ReliefWeb. Dengue-1 Outbreak, Tuvalu: Situational Report 25 March to 3 August 2019. 7 August, 2019.
  17. ReliefWeb. Dengue-1 Outbreak, Tuvalu: Situational Report 25 March to 10 August 2019 (Week 32, 4-10 August) 15 August, 2019.
  18. Rezza, G., 2016. Dengue and other Aedes -borne viruses: a threat to Europe? Eurosurveillance 21.
  19. Shi, L., Fu, S., Wang, L., Li, X., Gu, D., Liu, C., Zhao, C., He, J. ’an, Liang, G., 2016. Surveillance of mosquito-borne infectious diseases in febrile travelers entering China via Shenzhen ports, China, 2013. Travel Med. Infect. Dis. 14, 123–130.
  20. van Dodewaard, C.A.M., Richards, S.L., 2015. Trends in Dengue Cases Imported into the United States from Pan America 2001–2012. Environ. Health Insights 9, 33–40.
  21. Vincent, M., et al., From the threat to the large outbreak: dengue on Reunion Island, 2015 to 2018. Euro Surveill, 2019. 24(47).
  22. World Health Organization. Emergencies preparedness, response; Disease outbreak news; Dengue fever - Réunion, France; 1 May 2018. 2018.
  23. World Health Organization. Emergencies preparedness, response; Disease outbreak news; Dengue fever – Réunion, France; 20 May 2019. 2019.

Hepatitis A

NaTHNaC country-specific vaccine recommendations were based on a number of country variables including

  • endemicity in a country based on the age at midpoint of a population susceptibility to Hepatitis A (1),
  • incidence or risk of outbreaks defined as the number of cases per year obtained from Global Burden of Disease database 2019 (2)
  • World Bank income status of a country (3)

When there had been sporadic, absent or conflicting reports, confirmed recent outbreaks, or return traveller case reports, national authorities were consulted and a consensus opinion was formed based on consideration of any additional available data for that country. 

Updated: July 2023

  1. Jacobsen KH. Globalization and the Changing Epidemiology of Hepatitis A Virus. Cold Spring Harb Perspect Med. 2018;8(10):1-12. doi:10.1101/cshperspect.a031716
  2. Zeng DY, Li JM, Lin S, et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J Hepatol. 2021;75(3):547-556. doi:10.1016/j.jhep.2021.04.035
  3. Group TWB. World Bank Country and Lending Groups

Hepatitis B

NaTHNaC vaccine recommendations have been made for countries where 2% or more of the population were known to be persistently infected with the hepatitis B virus (intermediate/high prevalence) [1-3]. When there was limited information about those who are persistently infected with the virus in a country, a consensus opinion was formed based on consideration of the available data.

Updated: July 2014

Japanese encephalitis

NaTHNaC country-specific recommendations are based on the World Health Organization reported cases in 2013 to 2017 [1]. In addition, a literature review focussing on national ministry of health vaccine and mosquito control programmes reports, serological surveys and traveller case reports was completed [2- 20].

Where no or limited data was available, NaTHNaC worked with UKHSA to form a consensus opinion based upon the best available evidence.

Updated: February 2019

  1. World Health Organization vaccine-preventable diseases: monitoring system 2018 global summary.
  2. Bulletin of the World Health Organization. Estimated global incidence of Japanese encephalitis: a systematic review. Volume 89, Number 10, October 2011
  3. Centers for Disease Control MMWR June 2017: JE surveillance and immunization- Asia and Western Pacific Regions 2016
  4. Padbidri VS et al. A serological survey of arbovrial diseases among the human population of the Andaman and Nicobar Islands, India. Southeast Asian J Trop Med Public Health. 2002 Dec;33(4):794-800.
  5. Lindquist L. Recent and historical trends in the epidemiology of Japanese encephalitis and its implications for risk assessment in travellers. J Travel Med 2018 May 1;259 suppl_1): S3-S9.
  6. Fen Y et al, Distribution of Mosquitoes and Mosquito-Borne Viruses along the China-Myanmar Border in Yunnan Province. Jpn J Infect. Dis 65 (3), 215-221, 2012.
  7. Hills SL et al. Japanese encephalitis in Travelers from Non-Endemic Countries 1973-2008. Am. J. Trop. Med. Hyg., 2010; 82(5), pp. 930-936.
  8. Zhang H et al. Epidemiologic Survey of Japanese Encephalitis Virus Infection, Tibet, China, 2015. Emerg Infect Dis. 2017 Jun; 23(6).
  9. World Health Organization Strategic Advisory Group of Experts. Working Group Background Paper on Japanese Encephalitis Vaccines.1 October 2014.
  10. Wesley de Jong et al. Endemic and emerging acute virus infections in Indonesia: an overview of the past decade and implications for the future. Critical Reviews in Microbiology, 44:4, 487-503 (2018).
  11. Pavli A, Maltezou HC. Travel-acquired Japanese encephalitis and vaccination considerations. J Infect Dev Ctries 2015; 9(9):917-924.
  12. Im J et al. Protecting children against Japanese encephalitis in Bali, Indonesia. The Lancet 2018, Volume 391, Issue 10139, Pages 2500-2501.
  13. Bae W et al. Changes of Epidemiological Characteristics of Japanese Encephalitis Viral Infection and Birds as a Potential Viral Transmitter in Korea. J Korean Med Sci. 2018 Feb 26; 33(9): e70.
  14. Dong-Woo L et al. Epidemiology of Japanese encephalitis in South Korea, 2007-2010. International Journal of Infectious Diseases 2012 Vol 16(6), e448-e452.
  15. Kumar K et al. Japanese encephalitis in Malaysia: An overview and timeline. Acta Tropica 2018 Vol 185, 219-229.
  16. Oo PM et al. A Large Outbreak of Japanese Encephalitis in Rakhine State, Myanmar: Implication for Vaccine Policy. Outbreak, Surveillance and Investigation Reports 2016, Vol 9 (2), 8-16.
  17. Pant DK et al. Spatio-temporal epidemiology of Japanese encephalitis in Nepal, 2007-2015. PLoS One. 2017; 12(7): e0180591.
  18. Darwish MA et al. A sero epidemiological survey for certain arboviruses (Togaviridae) in Pakistan. Trans R Soc Trop Med Hyg 1983; 77 (4):442-5.
  19. Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and future prospects. Ther Clin Risk Manag. 2015;11:435-48.
  20. Nitatpattana N et al. Change in Japanese Encephalitis Virus Distribution, Thailand. 2008; Nov 14 (11):1762-1765.


NaTHNaC malaria recommendations follow current Public Health England malaria prevention guidelines for travellers from England, Wales and Northern Ireland [1].

Updated: July 2017


NaTHNaC country information pages include measles as a risk in all countries. All travellers should have received two measles containing vaccines in their lifetime or be immune because of measles disease, even if the country is declared by the World Health Organization to have eliminated measles.

Updated: October 2019

Meningococcal meningitis

NaTHNaC country-specific vaccine recommendations for meningococcal ACWY have been made if a country lies within the extended meningitis “belt” of sub-Saharan Africa, as defined by the World Health Organization. Additional vaccine recommendations for Saudi Arabia are made in accordance with the annual requirements of the Ministry of Health of the Kingdom of Saudi Arabia for those who will perform Hajj, Umrah or undertake seasonal work.

Updated: January 2021

Middle East respiratory syndrome coronavirus

NaTHNaC country-specific recommendations for countries with a known risk of Middle East respiratory syndrome coronavirus (MERS-CoV) is based on human cases reported globally to the World Health Organization (WHO) from 2014 to April 2020.

Recommendations for countries with a presumed risk of MERS-CoV are based on expert opinion and proximity to a country with reported cases.

Updated: 3 September 2020


NaTHNaC monitors the global polio situation, as detailed by the Global Polio Eradication Initiative (GPEI) and World Health Organization (WHO), and makes changes to country-specific recommendations as new information becomes available.

Some travellers to countries infected with wild poliovirus type1 (WPV1), circulating vaccine-derived poliovirus type 1 (cVDPV1) or type 3 (cVDPV3) should receive a booster dose of polio-containing vaccine if they are:

  • Immunosuppressed individuals and their household contacts, pregnant women, or others for whom live oral polio vaccine is contraindicated, who plan to travel to these countries for 4 weeks or more, if they have not had a polio containing vaccine within 12 months of their planned departure from the affected country.
  • Travellers to settings with extremely poor hygiene (e.g. refugee camps), or likely to be in close proximity with cases (e.g. healthcare workers) if they had not received vaccination in the past 12 months.

A booster dose of IPV-containing vaccine should also be considered for immunosuppressed individuals travelling for less than 4 weeks to an area with circulating wild or vaccine-derived virus if they have not received a dose within the previous 10 years.

Some travellers to countries infected with cVDPV2, with or without evidence of local transmission should receive a booster dose of polio-containing vaccine if they are:

  • Travelling to settings with extremely poor hygiene (e.g. refugee camps) or likely close proximity with cases (e.g. healthcare workers) if they have not received a dose in the last 12 months.
  • A booster dose should also be considered for immunocompromised travellers to areas with cVDPV if they have not received a dose in the last 10 years.

Travellers to countries considered by the WHO as no longer infected with either WPV or cVDPV, but which remain vulnerable to re-infection should ensure they are up to date with routine vaccination courses and boosters as recommended in the UK.

In a small number of countries, there may be variation of the recommendations above. This may be when new cases have been reported and we are waiting for guidance from World Health Organization, or environmental samples have detected cVDPV in specific areas.

Updated: May 2023


NaTHNaC worked with Public Health England to identify countries where rabies was currently a risk by reviewing data from the World Animal Health Information Database (OIE) until December 2019. Reports on the Outbreak Surveillance database were reviewed regarding known or presumed cases in indigenous domestic and/or wild animals. Where data was lacking for a country, other verifiable sources were sought including personal communications with the national authorities. Where no or limited data was available, a consensus opinion was formed based upon the best available evidence. Updates to these recommendations are made as required based on additional information as it becomes available.

Updated: April 2023


NaTHNaC reviewed available information in order to identify countries where schistosomiasis may pose a risk to travellers. The primary resource used was the World Health Organization (WHO) report on the status of schistosomiasis in endemic countries in 2021 [1]. Where reporting was sporadic or absent additional information was sought [2-6], UK returned traveller data considered and expert opinion sought, based on review of the available data.

Updated: August 2023

Tick-borne encephalitis

NaTHNaC country-specific recommendations for tick-borne encephalitis (TBE) are based on:

  • confirmed and reported human and animal TBE cases.
  • serological (blood testing) data in humans and animals.
  • TBE virus identified in animals and/or ticks.
  • national surveillance and TBE vaccination programmes.

In addition, information about animal/tick habitats, and proximity to known outbreak areas were used to interpret epidemiological data. If limited information was available for a country, vaccine recommendations were formed by consensus opinion, including geographical proximity to TBE endemic countries, based on most recent available information.

TBE country vaccine criteria and risk classification September 2023

Risk - countries with risk of TBE in all areas.
Human cases are reported annually, there is a national vaccination programme: vaccination is recommended for some travellers.

Some risk - there is a risk of TBE in some areas of this country.
Sporadic human cases are reported: vaccination is not usually advised but may be considered for some travellers.

Possible risk - human cases of TBE for this country are rare or not reported, but there is evidence of a possible risk.
Human cases are rare or have never been reported, but human sero-survey data or non-human TBE virus circulation has been identified and the country is adjacent to a known risk area: tick bite avoidance is recommended.

Updated: September 2023


There is an increased risk of acquiring tuberculosis (TB) in countries where the annual incidence of all forms of TB is ≥40 cases per 100,000 population and/or where the risk of Multi Drug Resistant -TB (MDR-TB) is high.

NaTHNaC reviewed the annual incidence of TB between 2017 and 2021 from the World Health Organization (WHO).

BCG vaccine may be recommended for some travellers when a country has:

  • reported an annual incidence of TB of ≥40 cases per 100,000 population at least once in the last five years (2017-2021).

BCG vaccine may be recommended for some travellers to some countries where the burden of Multi Drug Resistant-TB (MDR-TB) is considered as high according to the WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB) 2021 - 2025.

Where no or limited data is available for a country, expert consensus opinion is formed using the best available information. If the annual incidence is presumed to be ≥40 cases per 100,000 population, there is a recommendation for BCG vaccination for some travellers to that country in line with UKHSA Immunisation against Infectious Disease.

Updated: September 2023


NaTHNaC typhoid vaccine recommendations were based on a review of country-specific burden of typhoid disease using available resources [1-4] and Public Health England imported typhoid disease data. Where information was unavailable, the national authorities of a country were contacted for information and a consensus opinion was formed based on consideration of all available data for that country.

For those countries with typhoid disease incidence classified as “medium” the additional factor of sanitation levels in rural populations was considered to assess the need for a vaccine recommendation [1,5].

Vaccine was recommended for some travellers to a country, if the percentage of the rural population with access to improved sanitation was ≥ 80% as detailed in the WHO Progress on Drinking Water and Sanitation Report 2015. All other countries with “medium” disease incidence, where the access to improved sanitation was < 80%, vaccine was recommended for most travellers.

Updated: December 2018

  1. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Mogsdale V, Maskery B, Ochiai Rl et al, 2015. The Lancet Global Health Oct; 2(10):e570-80.
  2. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bulletin of the World Health Organisation, May 2004, 82(5), 346-353
  3. Antillion M et al, 2018. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. PLOS Neglected Tropical Disease; February 27, 2017, 1-21.
  4. Global Trends in Typhidal Salmoellosis: A Systematic Review. Als D, Radhakrishnan A, Arora P et al, 2018. Am. J. Trop. Med. Hyg., 99 (Suppl 3), 10-19.
  5. World Health Organization. Progress on Drinking Water and Sanitation Report 2015.

Yellow fever

NaTHNaC yellow fever vaccine recommendations are based on current WHO guidance on countries with a risk of yellow fever transmission [1, 2].

Updated: July 2017


NaTHNaC country-specific Zika recommendations are based on a formal Zika evidence review, supplemented by additional information from the World Health Organization, the European Centre for Disease Prevention and Control and the US Centers for Disease Prevention and Control [1-3].

Additional sources of information included UK Health Security Agency returned traveller data and further country specific literature searches. If limited information was available for a country, categorisation was agreed by consensus opinion, taking into account risk in bordering countries or areas.

Updated: December 2023
First published : 15 October 2015 Last updated : 28 December 2023

Explore more

Polio vaccination certificate

How to complete an International Certificate of Vaccination or Prophylaxis (ICVP) for polio

Updated: 25 January 2024

Educational events

A list of courses, conferences and study days of relevance to UK health professionals working, or wishing to work, in the field of travel medicine

Updated: 19 February 2024

The green book travel chapters

UK Health Security Agency Immunisation against infectious disease, the 'green book' travel chapter updates

Updated: 06 February 2024

'Getting to Grips...' online events and video guides

Online guides and webinar sessions for health professionals interested in travel health

Updated: 19 February 2024

Infectious diseases


Malaria is a serious and potentially life threatening disease, transmitted to humans through the bite of infected female Anopheles spp. mosquitoes

Updated: 13 February 2024

Yellow fever

Yellow fever is caused by a virus, which circulates between infected monkeys or humans and mosquitoes

Updated: 14 January 2020

Travellers' diarrhoea

Following advice on food and water hygiene is sensible, but travellers should always be prepared to manage the symptoms of travellers' diarrhoea

Updated: 06 February 2019

Preparing for healthy travel

Insect and tick bite avoidance

Protection from insect and tick bites is essential to help prevent vector-borne diseases such as malaria, yellow fever and Zika

Updated: 09 August 2020

Travel Insurance

Travellers must declare medical conditions when taking out travel insurance to ensure they are suitably covered

Updated: 26 September 2019

Sun protection

Enjoy the sun safely - limit your sun exposure, protect your skin and eyes to avoid damage from the sun’s ultra violet rays

Updated: 24 October 2018

Special risk travel/traveller

Neurological conditions

Information on pre-travel preparation, tips to stay healthy abroad and links to useful resources for travellers with neurological diseases

Updated: 24 September 2020

Areas of humanitarian crisis

For humanitarian aid workers and those advising those travelling to areas of conflict or disaster

Updated: 05 December 2019

Kidney (renal) conditions

Travel health advice for travellers and health professionals

Updated: 28 June 2022

Clinic resources

Educational events

A list of courses, conferences and study days of relevance to UK health professionals working, or wishing to work, in the field of travel medicine

Updated: 14 March 2017

'Getting to Grips...' online events and video guides

Online guides and webinar sessions for health professionals interested in travel health

Updated: 21 January 2024

Vaccines and medicines: availability, supply, shortages and use of unlicensed medicines

Information for health professionals on availability of vaccines and use of unlicensed products

Updated: 17 October 2022

Back to Top